Compare GXO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GXO | RYTM |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 2021 | 2017 |
| Metric | GXO | RYTM |
|---|---|---|
| Price | $58.65 | $84.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $67.91 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.0M | 778.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $13,178,000,000.00 | N/A |
| Revenue This Year | $6.81 | $55.34 |
| Revenue Next Year | $5.95 | $86.06 |
| P/E Ratio | $211.21 | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $34.80 | $55.31 |
| 52 Week High | $66.85 | $122.20 |
| Indicator | GXO | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 44.88 |
| Support Level | $51.93 | $82.98 |
| Resistance Level | $66.85 | $100.70 |
| Average True Range (ATR) | 1.75 | 3.50 |
| MACD | 0.77 | 0.59 |
| Stochastic Oscillator | 82.41 | 25.91 |
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.